Obstructive Sleep Apnea and Hypertension: Is Aldosterone Blockade the Optimal Approach to Control Blood Pressure and...

Area of Science:

• Cardiology
• Pulmonology
• Endocrinology

Background:

• Obstructive sleep apnea (OSA) is a prevalent condition strongly associated with systemic hypertension, including resistant and nocturnal forms.
• Current OSA therapies offer limited blood pressure (BP) reduction, leaving optimal antihypertensive strategies unclear for this patient group.

Purpose of the Study:

• To review the mechanisms of OSA-driven hypertension.
• To assess differential responses to standard OSA therapies.
• To evaluate mineralocorticoid-targeted treatments, including aldosterone blockade, for tailored BP lowering and airway improvement in OSA.

Main Methods:

• Review of existing literature on OSA, hypertension, and treatment responses.
• Analysis of mechanisms linking OSA to hypertension (intermittent hypoxia, sympathetic overactivity, RAAS activation, fluid shifts).
• Evaluation of clinical studies on standard OSA therapies (CPAP, oral appliances, weight loss) and mineralocorticoid receptor antagonists (MRAs) and aldosterone synthase inhibitors (ASIs).

Main Results:

• OSA contributes to hypertension through intermittent hypoxia, sympathetic overactivity, sleep fragmentation, RAAS activation, and nocturnal fluid shifts.
• Standard OSA therapies provide modest BP reductions (2-5 mmHg), with greater benefits in resistant hypertension, obesity, or high CPAP adherence.
• MRAs (spironolactone, eplerenone) have shown reductions in both apnea-hypopnea index (AHI) and BP in OSA patients with resistant hypertension.
• Emerging data on ASIs suggest BP reduction in obese hypertensive individuals, with OSA-specific outcomes pending.

Conclusions:

• Mineralocorticoid receptor antagonists represent a targeted strategy for managing hypertension in OSA patients, particularly those with resistant hypertension.
• Further research into aldosterone synthase inhibitors is warranted to explore their role in OSA and hypertension.
• Tailored antihypertensive strategies addressing OSA mechanisms are crucial for effective BP management in affected individuals.